These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35451470)

  • 41. LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters.
    de Moor WRJ; Williamson AL; Schäfer G; Douglass N; Gers S; Sutherland AD; Blumenthal MJ; Margolin E; Shaw ML; Preiser W; Chapman R
    Viruses; 2023 Jun; 15(7):. PubMed ID: 37515096
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization.
    Zhang QY; Zhang HQ; Zhang YN; Zhang ZR; Li XD; Hao MC; Zhang Y; Li JQ; Hu YY; Chen XL; Wang J; Shi YJ; Deng CL; Chen JJ; Ye HQ; Zhang B
    Antiviral Res; 2023 Dec; 220():105757. PubMed ID: 37984567
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
    J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters.
    Stark FC; Akache B; Deschatelets L; Tran A; Stuible M; Durocher Y; McCluskie MJ; Agbayani G; Dudani R; Harrison BA; Renner TM; Makinen SR; Bavananthasivam J; Duque D; Gagne M; Zimmermann J; Zarley CD; Cochrane TR; Handfield M
    Sci Rep; 2022 Jun; 12(1):9772. PubMed ID: 35697917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.
    O'Kennedy MM; Abolnik C; Smith T; Motlou T; Goosen K; Sepotokele KM; Roth R; du Preez I; Truyts A; Stark HC; Magwaza M; Mahanjana O; Verschoor JA; Moore PL; Lemmer Y
    Vaccine; 2023 Mar; 41(13):2261-2269. PubMed ID: 36868876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron.
    Zhu KL; Gao HX; Yao L; Rong J; Yang L; Zhang Z; Jiang P; Duan LJ; Wang GL; Dai EH; Ma MJ
    J Infect Dis; 2022 Nov; 226(9):1551-1555. PubMed ID: 35429398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant.
    To A; Wong TAS; Lieberman MM; Thompson K; Ball AH; Pessaint L; Greenhouse J; Daham N; Cook A; Narvaez B; Flinchbaugh Z; Van Ry A; Yalley-Ogunro J; Andersen Elyard H; Lai CY; Donini O; Lehrer AT
    ACS Infect Dis; 2022 Apr; 8(4):825-840. PubMed ID: 35263081
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
    Yahalom-Ronen Y; Tamir H; Melamed S; Politi B; Shifman O; Achdout H; Vitner EB; Israeli O; Milrot E; Stein D; Cohen-Gihon I; Lazar S; Gutman H; Glinert I; Cherry L; Vagima Y; Lazar S; Weiss S; Ben-Shmuel A; Avraham R; Puni R; Lupu E; Bar-David E; Sittner A; Erez N; Zichel R; Mamroud E; Mazor O; Levy H; Laskar O; Yitzhaki S; Shapira SC; Zvi A; Beth-Din A; Paran N; Israely T
    Nat Commun; 2020 Dec; 11(1):6402. PubMed ID: 33328475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity.
    Liao HC; Wu WL; Chiang CY; Huang MS; Shen KY; Huang YL; Wu SC; Liao CL; Chen HW; Liu SJ
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters.
    Wang S; Cui H; Zhang C; Li W; Wang W; He W; Feng N; Zhao Y; Wang T; Tang X; Yan F; Xia X
    Antiviral Res; 2023 Dec; 220():105765. PubMed ID: 38036065
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
    Honda-Okubo Y; Li L; André G; Leong KH; Howerth EW; Bebin-Blackwell AG; Ross TM; Petrovsky N
    Vaccine; 2023 Jul; 41(32):4710-4718. PubMed ID: 37355452
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity.
    Fluckiger AC; Ontsouka B; Bozic J; Diress A; Ahmed T; Berthoud T; Tran A; Duque D; Liao M; McCluskie M; Diaz-Mitoma F; Anderson DE; Soare C
    Vaccine; 2021 Aug; 39(35):4988-5001. PubMed ID: 34304928
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection.
    Ávila-Nieto C; Vergara-Alert J; Amengual-Rigo P; Ainsua-Enrich E; Brustolin M; Rodríguez de la Concepción ML; Pedreño-Lopez N; Rodon J; Urrea V; Pradenas E; Marfil S; Ballana E; Riveira-Muñoz E; Pérez M; Roca N; Tarrés-Freixas F; Cantero G; Pons-Grífols A; Rovirosa C; Aguilar-Gurrieri C; Ortiz R; Barajas A; Trinité B; Lepore R; Muñoz-Basagoiti J; Perez-Zsolt D; Izquierdo-Useros N; Valencia A; Blanco J; Guallar V; Clotet B; Segalés J; Carrillo J
    Nat Commun; 2024 Mar; 15(1):2349. PubMed ID: 38514609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Omicron-specific mRNA vaccine induced cross-protective immunity against ancestral SARS-CoV-2 infection with low neutralizing antibodies.
    Shen KY; Yang CH; Chen CT; Ho HM; Chiu FF; Huang CY; Liao HC; Hsu CW; Yu GY; Liao CL; Chen HW; Huang MH; Liu SJ
    J Med Virol; 2023 Jan; 95(1):e28370. PubMed ID: 36458553
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
    Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
    J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters.
    Li L; Honda-Okubo Y; Baldwin J; Bowen R; Bielefeldt-Ohmann H; Petrovsky N
    Vaccine; 2022 May; 40(23):3182-3192. PubMed ID: 35465982
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern.
    Renner TM; Akache B; Stuible M; Rohani N; Cepero-Donates Y; Deschatelets L; Dudani R; Harrison BA; Baardsnes J; Koyuturk I; Hill JJ; Hemraz UD; Régnier S; Lenferink AEG; Durocher Y; McCluskie MJ
    Front Immunol; 2023; 14():1182556. PubMed ID: 37122746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.